Lest we Forget: The Darker Side of the Hypocholesterolemic Statin Drugs

groupview

Abstract
Pharmacognosy Communications,2018,8,1,2-7.
Published:January-2018
Type:Original Article

Lest we Forget: The Darker Side of the Hypocholesterolemic Statin Drugs

Michael W Whitehouse, Desley E Butters

School of Medicine, Griffith University, Gold Coast Qld, AUSTRALIA.

Abstract:

Cholesterol-lowering statin drugs have been over-sold to the medical profession and over-prescribed by physicians, without due concern for their long-term disabling side-effects. These include acute renal failure, development of cataracts, diabetes, liver dysfunction and disabling myopathy. Most were predictable and have been well-documented: yet there has been little reduction in statin usage. The situation is made worse by more recent a) claims for off-label efficacy e.g. as anti-inflammatory agents and b) availability in some countries (e.g. UK) as over-the-counter medications.[1] Is it now time to carefully reconsider the need for such over-prescribing, with the promise of yet more to come (OTC availability, the ‘polypill’)?

Cite This Article

Vancouver Style :: Whitehouse MW, Butters DE. Lest we Forget: The Darker Side of the Hypocholesterolemic Statin Drugs. Pharmacognosy Communications. 2018;8(1):2-7.  (232.06 KB)
MLA Style: Whitehouse MW, Butters DE. Lest we Forget: The Darker Side of the Hypocholesterolemic Statin Drugs. Pharmacognosy Communications. 2018;8(1):2-7.  (232.06 KB)
CSE Style: Whitehouse MW, Butters DE. Lest we Forget: The Darker Side of the Hypocholesterolemic Statin Drugs. Pharmacognosy Communications. 2018;8(1):2-7.  (232.06 KB)
APA Style: Whitehouse MW, Butters DE. Lest we Forget: The Darker Side of the Hypocholesterolemic Statin Drugs. Pharmacognosy Communications. 2018;8(1):2-7.  (232.06 KB)

Founded:  In 2004, as the PHCOG.NET – a non-profit private organization dedicated to Natural Products Research leading to develop promising drugs. Our main mission is to make information on herbal drug research readily available in different formats to suit the individual needs.

Pharmacognosy Communications [Phcog Commn.] is a new quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the  publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.

The journal aims to cater the latest outstanding developments in the field of pharmacognosy and natural products and drug design covering but not limited to the following topics:

  • Pharmacognosy and pharmacognistic investigations
  • Research based ethnopharmacological evaluations
  • Biological evaluation of crude extracts, essential oils and pure isolates
  • Natural product discovery and evaluation
  • Mechanistic studies
  • Method and technique development and evaluation
  • Isolation, identification and structural elucidation of natural products
  • Synthesis and transformation studies

Distinctions:  The most widely read, cited, and known Pharmacognosy Communications and website is well browsed with all the articles published. More than 20,000 readers in nearly every country in the world each month

Aim and Scope | Editorial Board | Indexed & Abstracted | Instruction to Authors | Manuscript Submission & Charges

Subjects Covered : Natural Products, Pharmacognosy, Phytochemistry, Marine Pharmacognosy and Zoo Pharmacognosy
ISSN :2249-0159 (Print) ; 2249-0167 (Online) Frequency : Quarterly Rapid at a time publication (4 issues/year)

Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online  publication is 45 days.
Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.